The Role of TNF-\(\alpha\) in Mice with Type 1- and 2- Diabetes by Bhasin, Manoj et al.
 
The Role of TNF-\(\alpha\) in Mice with Type 1- and 2- Diabetes
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Koulmanda, Maria, Manoj Bhasin, Zuheir Awdeh, Andi Qipo,
Zhigang Fan, Dusan Hanidziar, Prabhakar Putheti, et al. 2012. The
role of TNF-\(\alpha\) in mice with type 1- and 2- diabetes. PLoS
ONE 7(5): e33254.
Published Version doi:10.1371/journal.pone.0033254
Accessed February 19, 2015 10:32:53 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10381374
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAThe Role of TNF-a in Mice with Type 1- and 2- Diabetes
Maria Koulmanda
1*
., Manoj Bhasin
2., Zuheir Awdeh
3, Andi Qipo
1, Zhigang Fan
1, Dusan Hanidziar
1,
Prabhakar Putheti
1, Hang Shi
4, Eva Csizuadia
1, Towia A. Libermann
2, Terry B. Strom
1*
1Departments of Surgery and Medicine, Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of
America, 2BIDMC Genomics and Proteomics Center, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Harvard Medical
School, Boston, Massachusetts, United States of America, 3Pulsar Clinical Technologies Inc., Cambridge, Massachusetts, United States of America, 4Department of
Internal Medicine, Wake Forest Health Sciences, Winston-Salem, North Carolina, United States of America
Abstract
Background: Previously, we have demonstrated that short-term treatment of new onset diabetic Non-obese diabetic (NOD)
mice, mice that are afflicted with both type 1 (T1D) and type 2 (T2D) diabetes with either Power Mix (PM) regimen or alpha1
antitrypsin (AAT) permanently restores euglycemia, immune tolerance to self-islets and normal insulin signaling.
Methodology and Principal Findings: To search for relevant therapeutic targets, we have applied genome wide
transcriptional profiling and systems biology oriented bioinformatics analysis to examine the impact of the PM and AAT
regimens upon pancreatic lymph node (PLN) and fat, a crucial tissue for insulin dependent glucose disposal, in new onset
diabetic non-obese diabetic (NOD) mice. Systems biology analysis identified tumor necrosis factor alpha (TNF-a) as the top
focus gene hub, as determined by the highest degree of connectivity, in both tissues. In PLNs and fat, TNF-a interacted with
53% and 32% of genes, respectively, associated with reversal of diabetes by previous treatments and was thereby selected
as a therapeutic target. Short-term anti-TNF-a treatment ablated a T cell-rich islet-invasive and beta cell-destructive process,
thereby enhancing beta cell viability. Indeed anti-TNF-a treatment induces immune tolerance selective to syngeneic beta
cells. In addition to these curative effects on T1D anti-TNF-a treatment restored in vivo insulin signaling resulting in
restoration of insulin sensitivity.
Conclusions: In short, our molecular analysis suggested that PM and AAT both may act in part by quenching a detrimental
TNF-a dependent effect in both fat and PLNs. Indeed, short-term anti-TNF-a mAb treatment restored enduring euglycemia,
self-tolerance, and normal insulin signaling.
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Introduction
A similar T cell dependent autoimmune process directed
against insulin producing beta cells creates type 1 diabetes (T1D)
in man and the clinically relevant non-obese diabetic (NOD)
mouse model [1,2]. Moreover, new onset T1D occurring in
NOD mice is associated with a type 2 diabetes mellitus (T2D)
like state, characterized by defective insulin signaling and thus
insulin resistance [3,4,5]. In the NOD model, robust expression
of pro-inflammatory cytokines within tissues in which insulin
directs disposal of glucose appears responsible for the defects in
insulin signaling and insulin triggered disposal of blood glucose
[4,5].
While many treatments prevent the development of diabetes in
NOD mice [2], few therapies have succeeded in restoring long-
term drug free euglycemia and immune tolerance to beta cells in
overtly diabetic NOD mice [5,6,7,8,9]. The beneficial effect of
anti-CD3 mAb in NOD mice served as the basis for initiating
clinical trials in which anti-CD3 treatment produced remissions in
select human subjects with new onset T1D [10,11]. In our
laboratory, treatment with either the Power Mix (PM) regimen
consisting of IL2.Ig, mutant antagonist-type IL15.Ig, and rapa-
mycin [5] or alpha1 anti-trypsin (AAT) [4] permanently restores
euglycemia, self-tolerance to islets and also eliminates insulin
resistance and defective insulin signaling in the NOD model [4,5].
To search for relevant therapeutic targets in new onset diabetic
NOD mice, we have applied genome wide transcriptional profiling
and systems biology techniques to examine the impact of PM [5]
and AAT [4] regimens upon pancreatic lymph nodes (PLN),
a disease relevant immune site, and fat, a site for insulin-dependent
glucose disposal.
As noted herein tumor necrosis factor alpha (TNF-a)
immerged as a potential therapeutic target for new onset
diabetes. Paradoxically, long-term treatment with tumor necrosis
factor alpha (TNF-a) [12] as well as short-term treatment with
anti-TNF-a [13] prevent the later development of diabetes in
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e33254NOD mice. Transgenic mice that express TNF-a solely in their
islets develop T1D more rapidly than wild type NOD mice [14].
Some advocate therapy with TNF-a or TNF-a inducers [15,16]
as treatment for overt T1D. Does neutralization of TNF-a confer
benefit or intensify T1D related autoimmunity in the therapeu-
tically challenging and apparently clinically predictive model of
new onset overt diabetes in NOD mice?
Results
Microarray and network based analysis of PLNs and fat
isolated from AAT and PM treated NOD mice identifies
TNF-a as a candidate target focus hub for reversing
diabetes
We hypothesized that gene expression changes occurring upon
onset of diabetes in NOD mice and reversed by different short-
term treatments that cure T1D/T2D may identify relevant
therapeutic targets. We performed transcriptional profiling in
combination with systems biology analysis on fat and PLNs
obtained from normoglycemic NOD (i.e., NOR), new onset
T1D/T2D NOD (DIA), as well as AAT and PM (only fat)
treated mice. We first identified the transcriptional changes
occurring upon new onset of T1D by comparing new onset
T1D/T2D fat, a site for insulin directed glucose entry, and PLN,
a relevant immune system site, gene expression profiles to fat and
PLN from normoglycemic mice. After preprocessing of gene
expression data, a total of 1,813 and 4,262 transcripts were
identified as significantly differentially expressed (fold change or
FC.2 and P value,0.05) in fat and PLNs, respectively, in
diabetic as compared to control normal mice. These gene
signatures are designated as the ‘‘Fat T1D/T2D signature’’ and
the ‘‘PLN T1D/T2D signature’’. The top differentially expressed
genes in PLNs are depicted in Fig. 1A, and hierarchical
clustering of these genes shows clear distinction between
normoglycemic and diabetic mice.
To identify the transcriptional changes induced by AAT or PM
treatment that reverse the diabetic phenotype, we performed an
analysis to identify the transcripts within the ‘‘Fat T1D/T2D
signature’’ and the ‘‘PLN T1D/T2D signature’’ that are counter-
regulated by the two treatments using K-means clustering of
differentially expressed transcripts. K-means clustering patterns
that depict the different degrees of counter-regulation induced by
the treatments on transcripts differentially expressed in diabetic
(DIA) vs. normal (NOR) NOD mice were identified. In fat tissue,
238 transcripts were counter-regulated by both AAT and PM
treatment by a magnitude of FC.2 and P value,0.05 (Table 1).
In PLNs, 1,367 transcripts were counter-regulated by FC.2 and P
value,0.05 in the AAT treatment group as compared to diabetic
mice (Fig. 1B). These results clearly demonstrate that a significant
portion of genes dysregulated during diabetes onset are reversed
by AAT or PM treatment in both fat and PLNs suggesting that
these sets of counter-regulated genes are critical for diabetes
development and have to be reversed in order to restore
normoglycemia.
To gain further insight into the impact of AAT treatment on
PLNs, we performed systems biology oriented analysis on the
1,367 transcripts showing an AAT induced reversal pattern, i.e.,
genes whose expression in PLNs resembles those of normal mice
following, but not before treatment, using Ingenuity Pathway
Analysis (IPA) 5.0 (www.ingenuity.com). This approach enabled
us to identify 10 interactive networks of genes with scores .15.
The network score is an indicator of significance, the higher the
score the more significantly the biological network is perturbed.
To understand the underlying biological mechanisms, we merged
the top 7 networks including genes related to inflammatory
response and cellular growth into one network. This interactive
network analysis incorporated additional genes into the network
that were not identified as differentially expressed in the counter-
Figure 1. Counter-regulation of gene expression by AAT or PM
as determined by DNA microarrays of normal (NOR), diabetic
(DIA) and AAT or PM treated PLNs and fat tissues from NOD
mice. The genes were identified in a supervised analysis using an
absolute fold change of 2 and P value,0.05. A) Hierarchical cluster
analysis of top transcripts that are differentially expressed in PLNs
extracted from diabetic mice vs. normal non-diabetic control mice. B)
Cluster analysis illustrating the transcripts that are significantly counter-
regulated by AAT treatment in PLNs. The columns represent the
samples and rows represent the genes. Gene expression is shown with
pseudocolor scale (21 to 1) with red denoting high gene expression
levels and green denoting low gene expression levels of genes.
doi:10.1371/journal.pone.0033254.g001
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formed regulatory or highly connected nodes that serve as focus
hubs in the networks, suggesting that these genes are targeted by
many other genes. The merged network was analyzed to identify
network hubs and bottlenecks, which may represent the key
regulatory nodes in the network. The key hubs in the network
were identified using degree of connectivity (number of
interactions for a node with other network genes). An interactive
network of the top 20 ranked focus gene hubs is shown in
Figure 2A. The detailed network of focus hubs and interacting
genes counter by AAT treatment is shown in Figure S1. The
focus hubs are formed by inflammation-regulated genes (e.g.,
TNF-a, NF-kB, TGF-b, IL6, IL-1b, VEGF), kinases (e.g. AKT,
PI-3 Kinase, P38 MAPK), and cell cycle/proliferation related
genes (ERK1/2, MYC) (Fig. 2B). Among these focus hub genes
TNF-a is the most highly connected gene, accounting for 53% of
the connections (Fig. 2B). Similar interactive network based
analysis on the fat counter-regulated genes (238) identified 5
significant networks (Score$40) related to cell cycle, lipid
metabolism and carbohydrate metabolism. The merging of the
three significantly effected networks generated a complex net-
work with regulatory hubs formed by inflammation related genes
(e.g. TNF-a, NF-kB), kinases (e.g. AKT, PI-3 kinase), and
transcriptional regulators (HNF4A, EGR1, Jnk) as well as
diabetes related genes (Insulin, Ins1) (Fig. 3). The top 20 ranked
focus gene hubs are shown in Figure 3A. The detailed network of
focus hubs and interacting genes counter by AAT and PW in fat
is shown in Figure S2. The focus gene hubs are likely critical for
overall function of the network and, thus, interruption of such
genes by therapeutic intervention is anticipated to perturb the
whole network of genes. Interestingly, interactive network based
analysis identified significant hubs formed by TNF-a, NF-kB,
AKT, and PI-3 kinase in both fat and PLNs. TNF-a again
emerged as the highest connected gene, accounting for 32% of
the connections. In fat and PLNs the treatments apparently result
in perturbation of similar and critical functional modules that are
associated with curative effects. TNF-a was identified as the
highest connected node in both PLNs and fat, respectively,
suggesting its critical role in curative effects.
Table 1. List of fold changes of the top 30 genes out of 238 genes counter-regulated by AAT and Power Mix treatment in fat.
SYMBOL GENE NAME Treatments
Diabetes AAT Power Mix
Ppbp pro-platelet basic protein 213.4 4.1 6.5
Net1 neuroepithelial cell transforming gene 1 211.1 7.7 14.7
Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic 29.3 12.6 13.6
Cd24a CD24a antigen 25.8 5.4 3.5
Egr1 early growth response 1 25.4 6.8 9.5
Rsad2 radical S-adenosyl methionine domain containing 2 24.3 3.8 2.5
Txnip thioredoxin interacting protein 23.9 3.6 4.0
Ptp4a1 protein tyrosine phosphatase 4a1 23.6 2.7 4.3
Crls1 cardiolipin synthase 1 23.6 2.2 4.1
Mycl1 v-myc myelocytomatosis viral oncogene homolog 1 23.0 2.3 2.6
Bnip3l BCL2/adenovirus E1B interacting protein 3-like 23.0 2.2 2.0
Ube2d3 ubiquitin-conjugating enzyme E2D 3 22.9 2.2 3.2
Isg20 interferon-stimulated protein 22.7 2.3 2.2
Ikbkg inhibitor of kappaB kinase gamma 22.6 2.6 2.9
Ccng2 cyclin G2 22.5 2.5 2.4
Psmd7 proteasome 26S subunit 22.5 2.0 2.0
Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 22.3 4.4 4.2
Bcap31 B-cell receptor-associated protein 31 2.3 22.4 22.5
Ccnd2 cyclin D2 2.5 22.7 22.4
Chst1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 2.6 22.1 22.3
Acaca acetyl-Coenzyme A carboxylase alpha 3.0 24.5 23.0
Ccnl2 cyclin L2 3.1 22.2 23.1
Mrc2 mannose receptor, C type 2 3.1 22.1 23.1
Igfbp5 insulin-like growth factor binding protein 5 3.7 22.6 23.7
Rpn1 ribophorin I 3.7 22.1 23.6
Rhof ras homolog gene family, member f 3.9 23.2 23.9
Camkk2 calcium/calmodulin-dependent protein kinase kinase 2 4.0 23.0 23.7
Pgd phosphogluconate dehydrogenase 5.2 24.1 25.3
Insig1 insulin induced gene 1 7.8 27.2 24.3
doi:10.1371/journal.pone.0033254.t001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e33254Figure 2. Counter-regulated network signature in PLNs. A) Interactive Network of top 20 focus gene hubs. B) Ranked list of top 20 focus gene
hubs on the basis of degree of connectivity. A merged network was generated from the top 7 networks of AAT treatment counter-regulated genes in
PLNs. The Ingenuity pathways analysis (IPA) tool was used to generate and merge the significantly effected networks from the AAT treatment
counter-regulated genes. The focus gene hubs were ranked in the merged network on the basis of degree of connectivity.
doi:10.1371/journal.pone.0033254.g002
Figure 3. Counter-regulated network signature in fat. A) Interactive Network of top 20 focus gene hubs. B) Ranked list of top 20 focus gene
hubs on the basis of degree of connectivity. The interactive network based analysis on the 238 fat counter-regulated genes identified 5 significant
networks (Score$40) related to cell cycle, lipid metabolism and carbohydrate metabolism. The merged network was generated from the top 3
networks of genes counter-regulated in fat by AAT and PM treatment. The focus gene hubs were ranked in the merged network on the basis of
degree of connectivity.
doi:10.1371/journal.pone.0033254.g003
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euglycemic state in new onset diabetic NOD mice
As noted above, the potential role of TNF-a in the pathogenesis
of diabetes is interesting and somewhat controversial. As our array
and pathways oriented approach (see above) suggested TNF-a as
the top focus gene hub, it is a potential therapeutic target linked to
NF-kB directed inflammation, another significant hub. Thus, we
tested the efficacy of a short course of anti-TNF-a in new onset
(.10 days) T1D/T2D NOD mice whose thrice-repeated blood
glucose levels ranged from 200 to 350 mg/dl. All untreated
diabetic NOD mice remained hyperglycemic despite daily insulin
therapy without spontaneous remissions (Table 2) and most died
within 7 weeks of onset of T1D. In contrast, long lasting (.200
days follow up) euglycemia (80–160 mg/dl) was rapidly (1–38
days) achieved in 22 of 24 anti-TNF-a, but not control, mAb
treated diabetic NOD mice despite cessation of anti-TNF-
a therapy (Table 2).
Anti-TNF-a treatment induces immune tolerance
selective to syngeneic beta cells in T1D NOD mice
As shown in Table 3, control untreated spontaneously new
onset T1D NOD recipients reject Non-Obese Diabetic- Severe
Combined Immunodeficiency mouse (NOD-scid) syngeneic or
C57BL/6 allogeneic islet grafts and become diabetic 4–21 or 5–8
days, respectively, post-transplantation (Table 3, Groups A and
B). To determine whether euglycemic anti-TNF-a treated spon-
taneously new onset T1D NOD mice were rendered tolerant to
their islets, we destroyed remnant beta cells through administra-
tion of streptozotocin (STZ) long-following (240–300 days)
cessation of anti-TNF-a therapy (Table 3, Groups C and D).
Subsequently syngeneic or allogeneic islet grafts were transplanted
into successfully treated NOD mice whose diabetic state was
rekindled with STZ administration (Table 3, Groups C and D).
Without re-institution of immunosuppressive therapy in hosts
previously treated with anti-TNF-a, all STZ treated recipients of
syngeneic (Table 3, Group C), but not allogeneic (Table 3,
Group D), islets became normoglycemic within 24 hours and
remained normoglycemic thereafter. Allogeneic islets transplanted
into spontaneously diabetic NOD mice treated with STZ are
rapidly rejected (Table 3, Group C). Hence, anti-TNF-
a treatment creates a drug-free tolerant state to syngeneic insulin
producing beta cells.
Islet histology, beta cells mass and circulating insulin
levels
Previous morphometric analysis of the insulin positive mass of
pancreatic islets revealed that NODs with blood glucose levels
between 250 mg/dl–350 mg/dl have about 25% of the insulin
positive beta cell mass of non-autoimmune NOD.SCID mice (5).
The 25% residual beta cell mass is similar to that found in newly
diagnosed patients with T1D. Histological and immunohisto-
chemical analysis was performed on islets from young 3-week-old
non-diabetic, age matched new onset diabetic NOD mice treated
with insulin or insulin plus anti-TNF-a. Islets from young non-
diabetic NOD mice revealed rare CD3+ mononuclear leukocytes
within the islets and abundant insulin expressing beta cells (Fig. 4
A&B). In new onset diabetic NOD mice a prominent intra- and
peri-islet CD3+ T cell rich process and grossly diminished
numbers of insulin staining beta cells are evident (Fig. 4 C&D).
Islets from anti-TNF-a treated new onset diabetic mice, similar to
islets from non-diabetic NOD mice, show normal numbers of
insulin expressing beta cells (Fig. 4 E&F). Only peri-islet, not islet
invasive, CD3+ T cells are present (Fig. 4 E&F). Thus, successful
treatment alters the insulitis from an invasive to a non-invasive
circumferential pattern.
Table 2. Short-term treatment of Diabetic NOD mice with anti-TNF-a treatment permanently restores euglycemia.
Treatment
Normoglycemia achieved
(range in days) Normoglycemic (%) Total number of mice used
NONE N/A 0% 150 (Historical controls)
NONE N/A 0% 20 (New controls)
Control mAb N/A 0% 10
Anti-TNF-a 1–38 92% 24
doi:10.1371/journal.pone.0033254.t002
Table 3. Short-term treatment of Diabetic NOD mice with anti-TNF-a therapy restores immune tolerance to beta cells.
Group DONOR (islets) RECIPIENTS TREATMENT SURVIVAL (days) Number of mice used
A NOD-scid NOD-sp NONE 4–21 5
B C57BL/6 NOD-sp NONE 5–8 20
C NOD-scid NOD-sp/stz* 240–300 days after
anti-TNF-a treatment
.70 11
D C57BL/6 NOD-sp/stz* 240–300 days after
anti-TNF-a treatment
3–11 7
NOD-sp spontaneous new onset diabetic NOD mice;
*NOD-sp/stz, a streptozotocin induced diabetic state was induced in NOD recipients. Spontaneously diabetic NOD mice (Groups C, D) were previously restored to
a euglycemic state by anti-TNF-a treatment. These mice remained euglycemic 240–300 days following the cessation of treatment.
Syngeneic NOD.SCID islet (Groups A, C) or allogeneic C57BL/6 (Groups B, D) islet grafts were transplanted into NOD recipients.
doi:10.1371/journal.pone.0033254.t003
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onset T1D/T2D NOD mice
Recent studies have revealed insulin resistance in new onset
diabetic NOD mice [3,5]. Hence we sought to determine whether
anti-TNF-atreatmentrestoresthesensitivityofNODmicetoinsulin
drivendisposalofbloodglucose.Bloodglucoselevelsin10-week-old
new onset diabetic mice fell only 37% over a 30 min period
followinganintraperitonealinjectionofinsulin,butdecreasedbyca.
80–85% in anti-TNF-a treated mice (Fig. 5). This pattern was also
noted in age matched control non-diabetic NOD mice (Fig. 5).
Thus, anti-TNF-a treatment ablates insulin resistance, thereby
normalizing the response of host tissues to insulin.
Anti-TNF-a treatment restores in vivo insulin signaling in
diabetic NOD mice
As insulin resistance in new onset diabetic NOD mice is
accompanied by defective in vivo insulin signaling in tissues that
are targeted for glucose disposal [4,5], we examined the effects of
anti-TNF-a upon insulin signaling in fat of new onset diabetic
NOD mice. Insulin-stimulated tyrosyl phosphorylation of the
insulin receptor (IR) was markedly (90%) diminished in new onset
T1D NOD mice, as determined by immunoblot densitometry,
compared to age matched control non-diabetic NOD mice
(Fig. 6A). Impaired insulin signaling was also evident with respect
to insulin-stimulated tyrosyl phosphorylation of insulin receptor
substrate-1 (IRS-1) (Fig. 6B), a molecule that normally transmits
the downstream signals of the insulin activated IR. The impact of
short term anti-TNF-a therapy upon tyrosyl phosphorylation
patterns in new onset T1D mice rendered euglycemic by anti-
TNF-a therapy was compared with that obtained with mice
rendered euglycemic from the time of diagnosis of overt diabetes
with intense insulin therapy delivered i.p. with osmotic pumps.
Anti-TNF-a therapy, unlike osmotic insulin pump therapy, does
not immediately render the treated mice euglycemic. We have
previously demonstrated that osmotic insulin pump therapy while
correcting hyperglycemia does not restore normal insulin-triggered
tyrosyl phosphorylation patterns [4]. Treatment with anti-TNF-a,
Figure 4. Immunohistochemical staining for CD3 and insulin in NOD pancreatic islets from different experimental groups.
Representative frozen sections from a 3 week old female pre diabetic NOD mouse without insulitis (A, CD3; B, insulin), a newly diagnosed diabetic
female mouse (C, CD3; D, insulin) and a diabetic NOD female mouse treated with anti-TNF-a (E, CD3; F, insulin). Overall the figures document
increasing cellular infiltration by CD3+ T cells and the associated loss of insulin positive cells in diabetic (C, D), as compared to prediabetic, hosts (A, B).
After anti-TNF-a treatment, intra-islet infiltration by CD3+ T cells is abolished with the appearance of a circumferential non-invasive CD3+ T cell
process (E). After treatment many islets are found with normal insulin+ beta cells (F).
doi:10.1371/journal.pone.0033254.g004
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insulin, completely restored the tyrosyl phosphorylation of IR and
IRS-1 in new onset T1D NOD mice. Anti-TNF-a treatment
apparently ablates insulin resistance via restoration of normal
tyrosyl phosphorylation dependent insulin signaling.
Discussion
Short-term treatment with PM [5] or with AAT [4] perma-
nently restores euglycemia, self-tolerance to islets, and also restores
effective insulin sensitivity/signaling [4,5]. As a means to search
for new therapeutic targets, we have applied genome wide
transcriptional profiling, systems biology, and pathway analysis
techniques to further examine the curative impact of PM [5] and
AAT [4] regimens upon pancreatic lymph nodes, a relevant
immune system site and fat, a site for insulin directed glucose
disposal, in new onset T1D/T2D NOD mice. Systems biology
analysis of the transcriptional profiles of animals treated with PM
or AAT identified TNF-a as the top focus gene hub, as determined
by the highest degree of connectivity, in both tissues. In PLNs and
fat TNF-a interacted with 53% and 32% of genes, respectively,
associated with reversal of diabetes by previous treatments. In
short, our molecular analysis suggested that PM [5] and AAT [4]
both may act in part by quenching a detrimental TNF-a de-
pendent effect in both fat and PLNs. Some investigators advocate
therapy with TNF-a or TNF-a inducers [15,16] as treatments for
autoimmune diseases including T1D. Nonetheless, we adminis-
tered neutralizing anti-TNF-a mAb short term to new onset
diabetic NOD mice. Gratifyingly, anti-TNF-a mAb administra-
tion to new onset T1D/T2D NOD mice served to enduringly
restore euglycemia, self-tolerance, and normal insulin signaling.
While many treatments prevent the occurrence of diabetes in the
NOD model, few permanently restore euglycemia and self-
tolerance. Indeed anti-TNF-a has been reported to prevent
diabetes but not restore euglycemia in overtly diabetic NODs
[12]. Our protocol for strict diabetes control, a protocol not used
in the previous study [12], was crucial to success as an adjunct to
anti-TNF-a treatment.
Previous studies have shown that an elevation of TNF-a levels
during the neonatal period in NOD mice increases the frequency
and hastened onset of T1D [13,14]. Injection of neutralizing anti-
TNF-a into newborn NOD mice results in complete prevention of
disease [13]. TNF-a may function in part by activating macro-
phages. As a consequence, activated macrophages may enter the
islets and begin to (i) recruit auto-reactive lymphocytes [17,18]; (ii)
process and present beta cell auto-antigens; and (iii) release pro-
inflammatory cytokines that promote effector type responses by
autoreactive T cells. That subtle inflammation, including critical
expression of TNF-a, is associated with and likely causal for obesity
linked T2D insulin resistance and faulty insulin signaling is well
appreciated [19]. Our new observations indicate that a similar
pattern of inflammation exists in both insulin sensitive (fat) and
pancreatic lymph nodes of new onset diabetic NOD mice in which
TNF-a is an important hub related to the pathogenesis of T1D and
T2D.OurdatadonotprovethatTNW–apersecausesdiabetes,but
the data, in keeping with the bioinformatics analysis showing this
molecule as a major hub in the disease, prove that in the NOD
mouse,diabetesisadependentprocess.Onecanspeculatetherapid
restoration of euglycemia was enabled by the ablation of insulin
resistance and ablation of the pro-inflammatory invasive insulitis
enabling dysfunction but not destroyed beta cells to resume insulin
production. It is notable that a small pilot trial with etanercept,
a soluble TNF-a receptor Ig fusion protein that binds to TNF-a,
showspromiseasatreatmentforchildrenwithnewonsetT1D[20].
Overall this study re-enforces the view that pro-inflammatory
cytokines play a cardinal role in T1D [4,5].
This study emphasizes the potential importance of analyzing
molecular pathways as a means to identify potential therapeutic
targets. There is a vast literature concerning the beneficial
therapeutic effects achieved by neutralizing TNF-a with antibodies
or circulating receptor proteins in a variety of autoimmune states
[21]. Neutralization of TNF-a in these states leads to profound
Figure 5. TNF-a treatment ablates insulin resistance in diabetic NOD mice. Insulin tolerance tests were performed in age matched NOD
mice (n=10/group): 1) new onset diabetic NOD mice; 2) anti-TNF-a treated new onset NOD mice; 3) age matched normoglycemic control NOD mice.
Food was withheld 3 hours before testing. Animals were weighted and blood samples collected at 0 minutes, animals were injected i.p. with 0.75 U/
kg of regular human insulin (Novolin, Novo Nordisk Pharmaceutical Industries, Inc. Clayton, NC). Blood samples were then collected at 15, 30 and
60 minutes. The blood glucose (BG) results were expressed as percentage of the baseline blood glucose concentration.
doi:10.1371/journal.pone.0033254.g005
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[21]. In this sense, the beneficial consequences of anti-TNF-a in the
clinically relevant new onset T1D NOD model might have been
foreseen despite suggestions that (i) TNW–a inducers might prove
therapeutic and (ii) TNF-a neutralizing therapy might prove
detrimental [15,16].
Methods
Ethics Statement
All mice were maintained under pathogen-free conditions at the
Harvard Institutes of Medicine (Boston, MA). The Harvard
Medical School institutional review board approved all animal
studies. The approved protocol number is #03827.
Mice
Female NOD (NOD/LtJx) mice and NOD.SCID (NOD.CB17-
Prkdc
scid/J) mice were purchased from Jackson Laboratories (Bar
Harbor, ME) at 4 wks of age.
Analysis of Gene Expression Data
Transcriptional profiles of fat and PLNs in normoglycemic
NOD mice (NOR), new onset diabetic (DIA), new onset diabetic
NOD mice treated with AAT or PM were characterized using the
Mouse 430 2.0 Affymetrix GeneChip, according to previously
described protocols for total RNA extraction and purification,
cDNA synthesis, in vitro transcription reaction for production of
biotin-labeled cRNA, hybridization of cRNA with mouse 430 2.0
Affymetrix gene chips, and scanning of image output files [22].
Raw data was submitted to NCBI Gene Expression Omnibus
(GEO) database (GEO accession number GSE33891). All
experiments were performed at least in duplicate on the fat and
PLN NOD tissue samples. The chip quality was determined using
the SimpleAffy package of Bioconductor [23]. To obtain the signal
values, chips were further analyzed using Robust Multichip
Average (RMA) method in R using Bioconductor and associated
packages. RMA performed the background adjustment, the
quantile normalization and final summarization of 11 oligonucleo-
tides per transcript using the median polish algorithm. When
comparing normal vs. diabetic mice, we used a non-parametric
method (RankProd) implemented as a Bioconductor package for
identification of differentially expressed genes [24]. For identifica-
tion of differentially expressed transcripts, P values were obtained
based on 100 random permutations in the RankProd package.
The genes that had P values less than or equal to 0.05 and absolute
fold change (FC) .2 between the normal and diabetic mice were
considered as differentially expressed.
To identify genes that are involved in the reversal of diabetes
after treatment with AAT or PM, we performed counter-
regulation analysis on the transcripts that are differentially
expressed between diabetic NOD and non-diabetic NOD (i.e.,
NOR) mice in fat and PLNs [4]. Counter-regulation means that
treatment down-regulates the genes that are up-regulated in
diabetic vs. normal mice and vice versa. K-means clustering of
Figure 6. Anti-TNF-a treatment restores insulin signaling in new onset diabetic NOD mice. A) Compares tyrosyl phosphorylation of the
insulin receptor in normal controls vs. newly diabetic and anti-TNF-a treated NOD mice. B) Compares tyrosyl phosphorylation of IRS-1 in normal
controls vs. newly diabetic and anti-TNF-a treated NOD mice. The left side shows representative immunoblots. The right side shows quantitative
analysis of the immunoblots. Mice (n=6–8/group) were fasted overnight and injected with human insulin (20 units/kg body weight i.p.) to acutely
stimulate insulin signaling. Mice were sacrificed 10 minutes later. Fat tissue obtained (50 days post-treatment) was dissected and frozen in liquid
nitrogen before immunoblotting analysis of insulin signaling proteins among i) normal non-diabetic NOD mice; ii) newly diagnosed diabetic NOD
mice treated with conventional insulin therapy; iii) anti-TNF-a treated NOD mice at 50 days post- treatment.
doi:10.1371/journal.pone.0033254.g006
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identify transcripts that are counter-regulated by treatments. Bins
of transcripts manifesting different degrees of counter-regulation
were identified and further filtered on the basis of magnitude and
P value based significance of counter-regulation. The final list of
counter-regulated genes was generated by considering genes that
are counter-regulated by a magnitude of fold change (FC) .2 and
P value,0.05 on treatment as compared to diabetic mice.
Interactive network, pathway and function analyses were
performed on significantly counter-regulated genes using In-
genuity Pathways Analysis (IPA 5.0) (www.ingenuity.com), a sys-
tems biology oriented package. The knowledge base of this
software consists of functions, pathways and network models
derived by systematically exploring the peer reviewed scientific
literature. This database consisting of millions of individually
modeled relationships between proteins, genes, cells, tissues, drugs,
and diseases for the identification of key functions and pathways
distinguishing biologic states. A detailed description of IPA
analysis is available at the Ingenuity Systems’ web site (http//
www.ingenuity.com). IPA calculates the P value using Fisher’s
Exact Test for each pathway and function according to the fit of
user’s data to the IPA database. The P value measures how likely
the observed association between a specific pathway/function/
interactive network and the data set would be if it was only due to
random chance, by also considering the total number of Function/
Pathway/Interactive Network eligible genes in the test dataset and
the reference sets of genes. The focus molecules were identified
from the integrated networks on the basis of degree of connectivity
(number of interactions for each gene). The focus hubs with higher
degrees of connectivity are considered critical for maintenance of
the networks, suggesting that therapeutic targeting of these focus
hubs may elicit the strongest impact.
Blood glucose
Blood glucose levels of NOD mice were monitored 2x/wk with
the Accu-Check blood glucose monitor system (Roche, Indianapo-
lis, IN). When non-fasting blood glucose levels are in excess of
200 mg/dl on three consecutive measurements a diagnosis of new
onset of diabetes is made. In practice, only mice with blood glucose
levels between 250 to 350 mg/dl became subjects in the anti-TNF-
a trial. Why? Previous morphometric analysis of the insulin positive
mass of the pancreatic islets revealed that NODs with blood glucose
levels between 250 mg/dl–350 mg/dl have about 25% of the
insulinpositivebetacellmassofnon-autoimmuneNOD.SCIDmice
[5].The25%residualbetacellmassissimilartothatfoundinnewly
diagnosed patients with T1D [25].
Treatment protocols
Individualized insulin therapy was employed and doses were
calibrated on the basis of three blood glucose measurements per
day. The goal was to maintain blood glucose levels between 100–
160 mg/dl. For blood glucose levels in excess of 160 mg/dl, NPH
insulin is given in doses ranging 1 to 4 International Units
depending upon the magnitude of hyperglycemia. Mice with high
blood glucose levels in excess of 400 mg/dl for 2 days also received
0.2–0.4 ml warm normal saline subcutaneously. For syngeneic
islet transplant recipients, blood glucose levels were checked at the
time of transplantation, then daily for 2 wks, and then 2–3x/wk.
The hamster clone IgG1 (TN3-19.12; Sigma St Louis, MO)
anti-TNF-a monoclonal antibody (mAb) was given to new onset
diabetic NOD mice at a dose of 100 mg intraperitoneal every
other day for 10 doses. Administration of an irrelevant hamster
isotype (hamster IgG1 clone G235-2356; BD, San Jose, CA) for
the same duration and dose served as a control treatment.
Streptozotocin (STZ) induction of diabetes
b-cells were destroyed in formerly spontaneously diabetic NOD
mice in which anti-TNF-a treatment rendered mice euglycemic by
administration of streptozotocin (STZ; 275 mg/kg intraperitone-
al), a beta cell toxin. STZ was administered between 220 to 320
days following the restoration of euglycemia and long following
cessation of anti-TNF-a treatment. With the re-emergence of
hyperglycemia following STZ administration, these diabetic NOD
mice were transplanted with syngeneic or allogeneic islets in the
absence of immunosuppressive therapy. Graft failure was defined
as the first day of 3 consecutive days of blood glucose levels
.250 mg/dl.
Islet transplantation
NOD.SCID or C57BL/6 mice (10–12 wks old) were used as
donors for islet transplants. After islet purification, islets with
diameters between 75 and 250 mm were hand picked and
transplanted under the renal capsule [26]. Each recipient received
600–800 NOD.SCID or C57BL/6 islets.
Insulin tolerance test
Insulin tolerance tests were performed as previously described
[4,5] in age matched NODs including 1) spontaneous new onset
diabetic NOD mice (NOD-sp); 2) anti-TNF-a treated spontaneous
new onset diabetic NOD mice (NOD-sp); and 3) non-diabetic
NOD mice. Blood samples were collected at 15, 30 and
60 minutes after insulin injections with results expressed as
a percentage of the initial blood glucose concentration [4,5].
In vivo insulin signaling studies
In vivo insulin signaling experiments were performed as
previously reported [4,5] on mice after a 16 hr fast. Mice were
injected i.p. with 20 U/kg of human regular insulin (Eli Lilly,
Indianapolis, IN) or saline and sacrificed 10 minutes later. Skeletal
muscle (gastrocnemius), fat (epididymal white adipose tissue) and
liver were dissected and frozen in liquid nitrogen for immuno-
blotting analysis of insulin signaling proteins and purification of
RNA. Immunoblotting for insulin receptor and IRS-1 phosphor-
ylation was performed as previously described [4,5].
Analysis of beta cell mass
Islet sections (5 mm) were immunostained (peroxidase-antiper-
oxidase) using rabbit anti-bovine glucagon (1:3000, gift of Dr. M.
Appel) or anti-insulin (1:200, Linco, Billerica, MA). Beta cell mass
was measured by point counting morphometry and beta cell
relative volume (intercepts over beta cells divided by intercepts
over total pancreatic tissue) was multiplied by the pancreas weight
to calculate the beta cell mass [27].
Analysis of pancreas infiltrating CD3+ T cells
Pancreases excised from anesthetized mice (non-diabetic, newly
diabetic and anti-TNF-a treated) were analyzed were fixed in
Bouin’s solution and embedded in paraffin or frozen sections.
Five-micron paraffin sections were mounted on charged Super-
frost Plus microscopy slides (Erie Scientific Company Portsmouth,
NH), air-dried overnight, and incubated at 56uC for 15 minutes.
Sections were then deparaffinized, and incubating slides in PBS
solution containing 0.3% hydrogen peroxide blocked endogenous
peroxidase activity. After blockade of ‘‘non-specific’’ binding with
horse serum, insulin staining with insulin primary antibody
(cat#A0564 Dako Corporation, Carpinteria, Calif., USA) was
performed on the sections. To identify CD3+T cells, the sections
were treated with heat mediated antigen retrieval (10 mM sodium
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serum. This was followed by overnight incubation at 4uC with the
primary antibody (CD3 antibody; cat#MCA1477 Serotec).
Staining procedures continue with application of biotin labeled
secondary antibodies (mouse anti-guinea pig cat# BA7000, mouse
anti-rat cat# BA4001 Vector Lab Inc., Burlingame, CA), and the
signal was enhanced with avidin-biotin complex-HRP (Elite
Standard, cat# PK-6100 from Vector Lab. Inc., Burlingame,
CA). The signal was visualized with ImmPACT DAB kit (cat#
SK-4105 Vector Lab. Inc., Burlingame, CA) and counter stained
with Gill’s hematoxylin II. The sections were analyzed with
Olympus BX51 microscope, DP71 camera sot program.
Supporting Information
Figure S1 Interactive Network representation of count-
er regulated genes in PLNs. The merged network was
generated from top 7 networks of AAT treatment counter
regulated genes in PLNs. The ingenuity pathways analysis (IPA)
tool was used to generate the networks from the AAT treatment
counter regulated genes and for merging the significantly effected
networks. The intensity of the node color indicates the degree of
up-regulation (red) and down-regulation (green) in treated mice as
compared with the diabetic PLNs. Top 20 Focus hubs are
highlighted in the network.
(JPG)
Figure S2 Interactive Network representation of AAT
and PM treatment counter regulated counter regulated
genes in fat. The interactive network based analysis on the fat
counter regulated genes (238) identified 3 significant networks
(Score$40) related to cell cycle, lipid metabolism and carbohy-
drate metabolism. The ingenuity pathways analysis (IPA) tool was
used to generate the networks from the AAT and PW treatments
counter regulated genes and for merging the significantly effected
networks. The intensity of the node color indicates the degree of
up-regulation (red) and down-regulation (green) in treated mice as
compared with the diabetic PLNs. Top 20 Focus hubs are
highlighted in the network.
(JPG)
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